|
|
Route 141 & Henry Clay Road
Wilmington, DE 19880 USA
phone:302-498-6700
fax:302-425-2750
|
|
| Symbol |
INCY |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.incyte.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| A pipeline of novel small molecule drugs. |
|
| Management |
| Paul A. Friedman, M.D., President and Chief Executive Officer; Patricia S. Andrews, Executive Vice President and Chief Commercial Officer; David C. Hastings, Executive Vice President, Chief Financial Officer; Brian W. Metcalf, Ph.D., Executive Vice President and Chief Drug Discovery Scientist; Patricia A. Schreck, Executive Vice President, General Counsel |
| |
|
|
|
|
|
|
|
| Keywords |
| inflammation, myeloproliferative, polycythemia, thrombocythemia, hematologic |
|
|
|
| Description |
|
Incyte's vision is a drug discovery and development company building a proprietary product pipeline of novel small molecule drugs. |
|
| Products / Services |
Incyte has recently entered into a collaborative license agreement for Dexelvucitabine or DFC (formerly called Reverset), a novel nucleoside analog reverse transcriptase inhibitor, which is in Phase II development to treat human immunodeficiency virus (HIV) infections.
|
|
| Technology / Differentiation |
| The Company has active internal drug discovery programs focused on the identification of novel small molecule drugs for inflammation, cancer and diabetes. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
